Curcumin, a plant-derived polyphenol, shows promise in hepatology for treating both malignant and non-malignant liver diseases and a subset of extrahepatic cancers. Curcumin has hepatoprotective, anti-inflammatory, antifibrotic, and antiproliferative properties, as is evident in preclinical and clinical studies. This highlights its potential as an adjunct to established cancer therapies, especially in the context of hepatocellular carcinoma and secondary liver malignancies. Curcumin also demonstrates potential in metabolic dysfunction-associated steatotic liver disease (MASLD), owing to its antifibrotic and lipid-lowering effects. However, its clinical use is limited, relating to its poor bioavailability and rapid metabolism. Nanotechnology, including liposomal and polymeric carriers, alongside synthetic curcumin derivatives, offers strategies to enhance the bioavailability and pharmacokinetic properties. We propose to revisit the use of curcumin in nanoparticle preparations in chronic liver disease and summarize current evidence in this review article.
姜黄素作为一种植物来源的多酚类化合物，在肝脏病学领域展现出治疗恶性与非恶性肝脏疾病及部分肝外癌症的潜力。临床前及临床研究证实，姜黄素具有保肝、抗炎、抗纤维化和抗增殖等多重药理特性，这使其有望成为现有癌症疗法（特别是肝细胞癌和继发性肝脏恶性肿瘤）的辅助治疗手段。凭借其抗纤维化及降脂作用，姜黄素在代谢功能障碍相关脂肪性肝病治疗中也显示出应用前景。然而，其生物利用度低、代谢迅速的特点限制了临床转化。以脂质体和聚合物载体为代表的纳米技术，结合人工合成的姜黄素衍生物，为改善其生物利用度和药代动力学特性提供了新策略。本文旨在重新审视纳米制剂姜黄素在慢性肝病中的应用价值，并对现有研究证据进行系统性综述。
肿瘤(癌症)患者之家